Post-Translational Modifications in Protein Therapeutics: Importance and Analytical Tools.

Emily E F Fekete, Huixin Lu, Xu Zhang

Abstract readReview

In one paragraph

Review in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Emily E F FeketeBiologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada.

Huixin LuBiologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada.

Xu ZhangBiologic and Radiopharmaceutical Drugs Directorate, Health Products and Food Branch, Health Canada, Ottawa, ON, Canada. xu.zhang@hc-sc.gc.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-translational modifications (PTMs) play a pivotal role in the activity and stability of proteins and can, therefore, significantly affect the quality of protein- or cell-based biological therapeutic products. Accordingly, PTMs are often evaluated as critical quality attributes, which require thorough characterization and evaluation throughout product development. Continued progress in understanding and characterizing protein PTMs is important to enable the distribution of safe and effective biologic medicines. Currently, a wide range of analytical techniques are employed for the detection and characterization of PTMs in the biopharmaceutical context. This chapter provides an overview of PTMs relevant to therapeutic proteins and commonly used or emerging analytical tools to analyze them.

Indexed as

Protein Processing, Post-TranslationalProteinsAnimalsAntibodies, MonoclonalHumansMass SpectrometryAntibodies, MonoclonalProteinsBiotherapeuticsMass spectrometryMonoclonal antibodyQuality attributes

Identifiers

PMID42542520

DOI10.3390/ph16020291

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.